Bill Ritter, a longtime, accomplished anchor for WABC-TV New York’s ABC7 Eyewitness News since 1999, recently announced that he had been diagnosed with ‘early-stage’ Alzheimer’s and stepped away from anchoring.
Ritter first noticed memory issues two years ago when he began forgetting people’s names and places. While he initially blamed his demanding work schedule, he scaled back his duties and hoped the symptoms would resolve. It was after he realized that his symptoms were not getting better that he went to his doctor to be evaluated.
During the 6 o’clock news broadcast on June 12, Ritter, whose father died of Alzheimer’s disease in 1998, shared that he is receiving treatments that are keeping the disease’s progression at bay for now.
Ritter’s announcement is a reminder of how much Alzheimer’s care has changed in recent years and how important early detection and treatment are in improving patient outcomes.
A History of Reactive Care
Early diagnosis has been one of the greatest challenges in Alzheimer’s disease care. For decades, doctors have had to rely on expensive brain scans, invasive lumbar punctures, or the appearance of clinical symptoms, often when the disease is already well established.
The pathway was familiar: Patients or their family members would notice a subtle change in memory. When the symptoms reached a point of concern, they would bring them up with their primary care doctor. A referral would be made, which often led to months of waiting to see a neurologist. By the time a diagnosis was given, the opportunity for even symptomatic treatment was significantly impacted.
The available treatment options for Alzheimer’s disease used to warrant a reactive strategy.
There was simply little to no available treatment to manage symptoms and the
increasingly rapid progression of disease and symptoms to the final stage of severe
dementia was inevitable. Thankfully, rapid advancements in diagnostics, biomarker research,
and therapies have changed what is possible.
A New Hope: Disease-Modifying Therapies
In a world where cancer screenings are the standard of care because we know that early evaluation and diagnosis can lead to better outcomes, cognitive assessments should be viewed in the same way. The numbers are staggering: the Alzheimer’s Association reports that more than 7 million Americans are living with the disease, and Alzheimer’s kills more people than breast cancer and prostate cancer combined.
For many years, an Alzheimer’s diagnosis came with only symptomatic treatment options. There was no treatment available that targeted the disease pathology, and patients faced an expectation of inevitable decline.
Today, thankfully, that narrative is changing. Emerging disease-modifying therapies, growing clinical research opportunities, and increasingly sophisticated diagnostic tools have changed the way that Alzheimer’s is found and treated, but only if early action is taken. Timing is critical.
New early intervention treatments, including FDA-approved amyloid-targeting therapies Kisunla and Leqembi, are most effective when symptoms are still as mild as possible. These treatments target the underlying biology of the disease, slowing progression in carefully selected patients and offering hope for individuals and families affected by Alzheimer’s.
The most critical time to get an accurate diagnosis and seek treatment is when a person first notices that something is “off” with their short-term memory and/or any other aspect of their “thinking ability.”
Just like with cancer, when Alzheimer’s is left untreated, the damage spreads throughout the brain, ultimately leading to severe dementia and death. If detected early, a person can seek new disease-modifying treatments, either those already on the market or through clinical trials.
The Future of Alzheimer’s Care: Biomarkers and Diagnostic Innovations
Alzheimer’s diagnostics are becoming faster, more scalable, and more practical, with a greater number of treatment options available than ever before.
One of the most promising developments is less invasive diagnostic methods, including blood-based biomarkers.
Biomarkers allow doctors to identify the biological processes of Alzheimer’s disease with precision, often before symptoms become disabling. Because amyloid-targeting therapies are most effective when symptoms are minor, biomarkers are not just a diagnostic tool: they are a gateway to treatment.
Research trials are currently underway exploring whether a simple finger-prick blood-based biomarker test can provide an early Alzheimer’s diagnosis.
Advocating for the Advancement of Alzheimer’s Treatment
While Bill Ritter is stepping away from the news desk, he announced he will continue covering special projects for Eyewitness News focused on Alzheimer’s and related conditions. I applaud Mr. Ritter and the entire WABC-TV team for shining a light on this critical topic that affects so many patients and their families throughout the US.
This announcement is an important reminder that no one should ignore changes in their memory or thinking. By having these important conversations earlier, broadening access to diagnostic testing, and raising awareness of available and emerging treatment options, we can help ensure that more people get the care, support, and opportunities they need early enough to make a meaningful difference.